Multiple Sclerosis
-
Interactive Tool: Disease Modifying Therapies Drove 82% of Total Increase in Health Care Spending for People with Multiple Sclerosis
Read more: Interactive Tool: Disease Modifying Therapies Drove 82% of Total Increase in Health Care Spending for People with Multiple SclerosisIn a recent issue brief, HCCI found that the already high cost of care for people with multiple sclerosis (MS) rose dramatically over the past several years. The primary driver was the increasing cost of a small group of prescription drugs called Disease Modifying Therapies (DMTs). To illustrate the role prescription drug prices play in…
-
Health Exec: Drug competition didn’t stop sharp increase in MS spending
Read more: Health Exec: Drug competition didn’t stop sharp increase in MS spendingBy: John Gregory Between 2009 and 2015, spending on patients with multiple sclerosis (MS) greatly increased, with disease modifying therapies (DMTs) accounting for 82 percent of that increase as prices jumped every year and use slightly declined. The report from the Health Care Cost Institute (HCCI) examined claims for people with MS from 2009 to…
-
The Rising Cost of Specialty Drugs Drove Spending Increases for People with Multiple Sclerosis
Read more: The Rising Cost of Specialty Drugs Drove Spending Increases for People with Multiple SclerosisThis issue brief investigates how the cost of prescription drugs affects the total cost of care for people with multiple sclerosis (MS). It decomposes total health care spending by category, specifically separating out spending on specialty drugs used to treat MS, called Disease Modifying Therapies (DMTs). The issue brief subsequently examines whether changes in spending…